endpts.com
Open in
urlscan Pro
13.32.27.15
Public Scan
Submitted URL: https://e.endpointsnews.com/t/t-l-vtutjtd-jhdldljikl-m/
Effective URL: https://endpts.com/atreca-lays-off-40-of-remaining-workers-as-it-seeks-strategic-alternatives/
Submission: On November 17 via api from US — Scanned from DE
Effective URL: https://endpts.com/atreca-lays-off-40-of-remaining-workers-as-it-seeks-strategic-alternatives/
Submission: On November 17 via api from US — Scanned from DE
Form analysis
1 forms found in the DOMhttps://endpts.com/
<form action="https://endpts.com/">
<input type="text" name="s" placeholder="Search">
<button class="epn_ux_button epn_white epn_search_submit_button"></button>
</form>
Text Content
* Channels * All News * In Focus * Special * AI * Bioregnum * Biotech Voices * Cell/Gene Tx * China * Coronavirus * Deals * Diagnostics * Discovery * FDA+ * Financing * Health Tech * Law * Letters to the Editor * Manufacturing * Marketing * Opinion * Outsourcing * Peer Review * People * Pharma * R&D * Startups * Weekly * Webinars * Biopharma Jobs * More * Work at Endpoints * Letter to Editors * IPO Tracker * Webinars * Events * Sponsored Posts * Advertise * Privacy Policy * Endpoints Merch * About Us * Help * SIGN UP * LOG IN November 15, 2023 07:23 AM EST People THREE MONTHS AFTER BIG REORGANIZATION, ANTIBODY MAKER ATRECA IS BACK WITH ANOTHER ROUND OF LAYOFFS AMBER TONG SENIOR EDITOR Atreca is letting another 40% of its staff go in a move expected to keep itself afloat through the first quarter of 2024 as it explores strategic alternatives. The biotech is focused on advancing APN-497444, an antibody-drug conjugate targeting a tumor-specific glycan, through preclinical testing. Its funding needs for that program and other follow-up ADCs, coupled with current financial market conditions, led to the decision, Atreca CEO John Orwin said. UNLOCK THIS ARTICLE INSTANTLY BY BECOMING A FREE SUBSCRIBER. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER TRENDING NOW ASTELLAS DETAILS POTENTIAL REASON BEHIND DEATHS IN RARE DISEASE GENE THERAPY TRIAL Q&A: CAN ONCOLYTIC VIRUSES MAKE A COMEBACK? EXPERTS DISSECT CLINICAL FAILURES AND OUTLINE PATH FORWARD DESIGN THERAPEUTICS HINTS AT ‘STRATEGIC REALIGNMENT,’ REPLACES CEO; KARYOPHARM CO-FOUNDER LEADS ATP'S NEREID ASTRAZENECA LANDS FDA APPROVAL FOR AKT INHIBITOR IN BIOMARKER-DEFINED BREAST CANCER SUBSET LILLY INVESTS $2.5B IN NEW GERMAN SITE TO BOOST TIRZEPATIDE SUPPLY, $100M FOR LOCAL BIOTECHS sponsored CLINICAL STUDIES IN JAPAN TODAY: ANOTHER LOOK AT THE WORLD’S SECOND-LARGEST PRESCRIPTION DRUG MARKET IN A ... Bioscience & Technology Business Center The University of Kansas Lawrence, Kansas LATEST * All News * Special * In Focus CHANNELS * AI * Bioregnum * Biotech Voices * Cell/Gene Tx * China * Coronavirus * Deals * Diagnostics * Discovery * FDA+ * Financing * Health Tech * Law * Letters to the Editor * Manufacturing * Marketing * Opinion * Outsourcing * Peer Review * People * Pharma * R&D * Startups * Weekly MORE * Work at Endpoints * Letter to Editors * IPO Tracker * Events * Webinars * Sponsored Posts * Advertise * Endpoints Merch * About Us * Help WORK IN BIOTECH * Endpoints Careers © Endpoints News 2023 * Help * Advertise * Privacy Policy * Business Model LOG IN TO YOUR ACCOUNT EMAIL PASSWORD Change my password Get a magic email link LOG IN REQUEST MAGIC LINK If you're already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours. EMAIL BACK REQUEST RESET PASSWORD We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours. EMAIL BACK RESET SIGN UP FOR FREE TO READ A LIMITED NUMBER OF ARTICLES EACH MONTH. ABOUT YOU NEWSLETTER INTERESTS PICK WHAT NEWSLETTERS GET DELIVERED TO YOUR INBOX EACH WEEK. Biopharma ENDPOINTS NEWS Daily at 11:30 AM ET EARLY EDITION Daily at 7:15 AM ET ENDPOINTS PHARMA Daily at 2 PM ET BREAKING NEWS ALERTS 2-3 times a week ENDPOINTS MARKETING RX Tue at 2 PM ET ENDPOINTS FDA+ Wed at 2 PM ET ENDPOINTS MANUFACTURING Thu at 2 PM ET ENDPOINTS WEEKLY Sat at 6 AM ET Healthcare ENDPOINTS HEALTH TECH Coming soon INSTANT SIGN UP Want unlimited access? Sign up for a premium subscription plan.